Mark J. Cooper
Impact in
- Pharmaceutical Science top 0.5%
- Advanced Drug Delivery Systems
- Biomaterials top 2%
- Nanoparticle-Based Drug Delivery
Papers in
-
- RNA Interference and Gene Delivery 41
- Retinal Development and Disorders 12
-
- Advanced Drug Delivery Systems 7
- Co-authors
- Muna I. Naash (17 shared papers)Shannon M. Conley (9 shared papers)Rasha S. Makkia (9 shared papers)Pamela B. Davis (4 shared papers)Zongchao Han (6 shared papers)Susannah L. Hyatt (7 shared papers)Linas Padegimas (14 shared papers)Murali K. Pasumarthy (4 shared papers)
- Journals
- Molecular Therapy (7 papers)Journal of Controlled Release (5 papers)The FASEB Journal (4 papers)Investigative Ophthalmology & Visual Science (4 papers)PLoS ONE (4 papers)
- Partner nations
- United StatesIsraelGermany
In The Last Decade
Mark J. Cooper
54 papers receiving 2.9k citations
Peers
Comparison fields: 5 of 79
- Pharmaceutical Science 491
- Biomaterials 375
- Molecular Biology 1.8k
- Ophthalmology 143
- Drug Discovery 4
Countries citing papers authored by Mark J. Cooper
This map shows the geographic impact of Mark J. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Cooper more than expected).
Fields of papers citing papers by Mark J. Cooper
This network shows the impact of papers produced by Mark J. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Cooper. The network helps show where Mark J. Cooper may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark J. Cooper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 247 | |
| 2 | 2006 | 180 | |
| 3 | 2003 | 164 | |
| 4 | 2003 | 145 | |
| 5 | 1988 | 143 | |
| 6 | 2001 | 136 | |
| 7 | 2012 | 127 | |
| 8 | 2007 | 124 | |
| 9 | 2006 | 122 | |
| 10 | 2009 | 109 | |
| 11 | 2009 | 96 | |
| 12 | 2011 | 84 | |
| 13 | 2011 | 81 | |
| 14 | 2003 | 79 | |
| 15 | 2003 | 78 | |
| 16 | 1995 | 77 | |
| 17 | 2012 | 73 | |
| 18 | 2009 | 69 | |
| 19 | 2013 | 69 | |
| 20 | 2009 | 65 |
About Mark J. Cooper
Mark J. Cooper is a scholar working on Molecular Biology, Pharmaceutical Science, Neurology, Genetics and Pulmonary and Respiratory Medicine, having authored 54 papers that have together received 3.1k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (41 papers), Retinal Development and Disorders (12 papers), Advanced Drug Delivery Systems (7 papers), Parkinson's Disease Mechanisms and Treatments (3 papers), Virus-based gene therapy research (3 papers), Nanoparticle-Based Drug Delivery (2 papers), Inhalation and Respiratory Drug Delivery (2 papers) and Cystic Fibrosis Research Advances (2 papers). The work is most often cited by research in Pharmaceutical Science (491 citations), Biomaterials (375 citations), Molecular Biology (1.8k citations), Ophthalmology (143 citations) and Drug Discovery (4 citations). Mark J. Cooper has collaborated with scholars based in United States, Israel and Germany. Frequent co-authors include Muna I. Naash, Shannon M. Conley, Rasha S. Makkia, Pamela B. Davis, Zongchao Han, Susannah L. Hyatt, Linas Padegimas, Murali K. Pasumarthy, Robert C. Moen and Alexander B. Quiambao. Their work appears in journals such as Molecular Therapy, Journal of Controlled Release, The FASEB Journal, Investigative Ophthalmology & Visual Science and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.